Constellation Pharmaceuticals Inc
33.97 - 34.05
0 - 34.05
Join Discuss about CNST with like-minded investors
Upside: -CNST +67% (to be acquired by Morphosys for $34.00/shr in cash; deal valued at $1.7B) -MITO +42% (receives Orphan Drug Designation from the European Medicines Agency for elamipretide for the treatment of Barth syndrome) -SLCT +21% (First Bancorp to acquire Select Bancorp, Inc. for $18.10/shr in $314M all-stock transaction) -AMC +20% (successfully sold 8.5M shares of its Class A common stock to Mudrick Capital Management, LP; launches AMC Investor Connect) -MDLA +11% (earnings, guidance) -KIN +9.8% (announces positive results from pivotal efficacy study of parvovirus monoclonal antibody for the prevention of deaths in dogs infected by parvovirus) -WORX +9.6% (Interim COO Tim Hannibal to become permanent CEO) -RLX +7.4% (earnings, guidance) -SKLZ +6.7% (acquires technology-driven marketing platform Aarki for $150M cash-stock deal) -SCYX +4.3% (announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections) -FUSN +3.8% (enters into agreement with McMaster University to build radiopharmaceutical manufacturing facility) -SFT +3.3% (executives announce purchase of shares) -AMBA +3.1% (earnings, guidance) -EVOK +2.2% (issued new US patent covering methods of use for Gimoti (metoclopramide) nasal spray) -APPS +1.9% (earnings, guidance) -CANF +1.9% (to Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson) -ETSY +1.3% (acquires global fashion resale marketplace Depop for $1.63B consisting primarily of cash) -AAP +1.2% (earnings, guidance) -KODK +1.2% (issues statement responding to New York Attorney General regarding insider trading evidence) -ZM +1.2% (earnings, guidance) Downside: -IRTC -15% (CEO Michael Coyle steps down due to personal matters; affirms select Q2 guidance) -ENG -14% (registers ~7.14M shares at $2.80/shr) -LIZI -6.8% (earnings) -PROG -4.2% (launches strategic transformation into biotech company) -ADCT -4.1% (files to sell up to 5.6M shares for holders) -OMIC -3.1% (underwriters fully exercise 1.5M share overallotment option) -HPE -1.2% (earnings, guidance
66 Replies 9 👍 10 🔥
Next Dividend Date
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.